<DOC>
	<DOCNO>NCT01794429</DOCNO>
	<brief_summary>To examine 3 month treatment GLP-1 ( glucagon-like-peptide-1 ) analogue induce weight loss obese , non-diabetic patient diagnosis within schizophrenic spectrum . The investigator also examine possible association GLP-1 treatment peripheral metabolic parameter change body fat HbA1c . Moreover , GLP-1 analogue treatment associate effects/changes cognition subjective quality life . Possible cerebral effect ( pro-cognitive ) GLP-1 analogue treatment associate correlated change brain , functional magnetic resonance imaging ( fMRI ) .</brief_summary>
	<brief_title>Treatment Antipsychotic-associated Obesity With GLP-1 Analogue</brief_title>
	<detailed_description>The primary endpoint weight loss 3 month treatment GLP-1 analogue exenatide ( Bydureon® ) . Secondary endpoint comprise physiological/metabolic parameter cognitive measurement : - Metabolic endpoint include amongst others : change body fat ( DEXA-scan ) change HbA1c ( average blood glucose level ) , cholesterol triglyceride . Moreover physiological effect examine eg possible effect central/peripheral bloodpressure heart rate . - Cerebral endpoint investigate via functional magnetic resonance imaging ( fMRI ) ; include potential neuroprotective effect exenatide . The main focus potential hippocampal volume change potential change cerebral blood flow . Functional MRI provide data image correlate cognitive test questionnaire . - Cognitive endpoint comprise potential improvement cognition focus specific memory test ( BACS , DART Rey 's Complex Figure ) possible improvement subjective quality life ( questionnaire ) .</detailed_description>
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Metabolic Syndrome X</mesh_term>
	<mesh_term>Antipsychotic Agents</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Age : 18 65 year Diagnosis schizophrenia spectrum ( ICD10 : F20.x , F25.x ) inpatients outpatient include Current unchanged treatment least one antipsychotic drug ( FGA and/or SGA and/or depot treatment ) BMI ≥30 kg/m2 HbA1c &lt; 6,5 % Substance dependence ( ICD10 : F1x.2 ( apart nicotine addiction F17.2 ) ) Diabetes HbA1c ≥6.5 % Contraindications MRI ( metal implant , pacemaker , severe claustrophobia , ≥150 kg ( max . bed weight MRI scanner ) ) Previous head trauma loss consciousness 5 minute Pregnancy ( screen urine human chorionic gonadotropin ( hCG ) , lactation acceptance use effective contraception intervention period Severe somatic disease , include inflammatory bowel disease chronic ketoacidosis Allergy exenatide Coercive measure accord Danish Law Psychiatry condition accord sponsor congruous participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Obesity</keyword>
	<keyword>The Metabolic Syndrome/disturbances</keyword>
	<keyword>Drug-induced adipositas</keyword>
	<keyword>Schizophrenia</keyword>
	<keyword>GLP-1 analogue</keyword>
	<keyword>cerebral effect</keyword>
</DOC>